RCS - Angle PLC - Launch of PD-L1 test to support cancer studies

AngleAnnouncement

09/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231109:nRSI8568Sa&default-theme=true

RNS Number : 8568S  Angle PLC  09 November 2023

 For immediate release  9 November 2023

 

ANGLE plc ("the Company")

 

ANGLE LAUNCHES PD-L1 TEST TO SUPPORT CANCER THERAPY STUDIES

 

ANGLE's Portrait PD-L1 test uses CTCs harvested from the Parsortix system to
investigate real-time patient PD-L1 status for clinical studies

 

 The test is designed for highly accurate, repeatable, and precise results
for CTC PD-L1 biomarker expression

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) diagnostic solutions for use in
research, drug development and clinical oncology, is delighted to announce the
launch of its Portrait(®) PD-L1 test for the evaluation of PD-L1 protein
expression on CTCs following extensive development and optimisation. The test
is provided as a service from ANGLE's Onc-ADaPT(®) GCP-compliant laboratories
and is conducted by an expert team with over 10 years' experience in CTC
analysis.

 

PD-L1 is an immune-related biomarker that can be expressed on the surface of
tumour cells across a range of cancer types, and expression of this biomarker
enables cancer cells to evade immune response mechanisms that would typically
keep abnormal cell growth in check. Consequently, PD-1/PD-L1 inhibitors have
emerged as the leading immunotherapy treatment option with over 2,800 active
interventional studies in progress involving 430,000 patients.

 

The output of current tumour tissue-based PD-L1 tests varies considerably,
with poor performance often unavoidable due to the elapsed time between tissue
biopsy (generally taken at diagnosis and difficult or impossible to repeat)
and disease progression (which may be months or years later) when
immunotherapies are considered, during which time PD-L1 status can change.
ANGLE has developed its immunofluorescence (IF) based test for the
determination of PD-L1 status on CTCs to allow real-time assessment of
biomarker status, which may address this fundamental flaw in current PD-L1
tests via a simple blood test.

 

ANGLE's Portrait PD-L1 service is an end-to-end solution using ANGLE's world
leading Parsortix CTC technology to deliver:

 

·    minimally invasive liquid biopsy with sample stability up to five
days post-blood collection

 

·    biomarker independent harvest of phenotypically diverse CTCs from a
simple blood test

 

·    identification and enumeration of CTCs with accurate, precise
assessment of PD-L1 status (see
https://angleplc.com/onc-adapt-laboratories/portrait-pd-l1/
(https://angleplc.com/onc-adapt-laboratories/portrait-pd-l1/) )

 

·    longitudinal monitoring of PD-L1 status over multiple time points
including before, during and after the patient receives the treatment.

 

It is well established that the number of CTCs is prognostic of cancer
treatment response, recurrence, and relapse and this has been documented in
numerous peer-reviewed publications. It is now evident that changes in CTC
numbers and their PD-L1 status can provide an early indication of
immunotherapy treatment resistance and progressive disease. Studies have also
shown that CTCs isolated from patients with solid cancers and expressing PD-L1
may serve as a clinically actionable biomarker for immunotherapy.

 

The global PD-1 and PD-L1 immunotherapy market is currently valued at US $36.9
billion per annum, and analysts predict the market to reach US $109.1 billion
by 2032. Despite the rapid expansion of the immunotherapy market, with many
indications approved under accelerated approval, this class of drug has been
challenged by the withdrawal of a range of indications due to the failure to
subsequently confirm the clinical benefit in such indications in larger
trials. As such, a test that can help with patient stratification in
biopharmaceutical drug trials, and act as an early predictor of treatment
response and disease recurrence could provide earlier insight into critical
efficacy endpoints.

 

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"Whilst immune checkpoint inhibitors have achieved remarkable progress in
tumour treatment, the cost of treatment is high and currently the majority of
patients fail to respond.

 

ANGLE's Portrait PD-L1 test provides accurate, repeatable, and precise PD-L1
identification on CTCs and hence has the potential to streamline patient
selection and optimise PD-L1 monitoring for treatment response and disease
progression throughout clinical studies.

 

We are now beginning an active promotion of this test to biopharma customers."

 

 

For further information:

 

 ANGLE plc                                   +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Joint Broker)          +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 Jefferies (Joint Broker)                    +44 (0) 20 7029 8000

 Thomas Bective, Shaam Vora, Alexander Ind

 FTI Consulting

 Simon Conway, Ciara Martin                  +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                    +1 (212) 850 5624

 

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) diagnostic solutions for use in research, drug development
and clinical oncology using a simple blood sample. ANGLE's FDA cleared and
patent protected circulating tumour cell (CTC) harvesting technology known as
the Parsortix(®) PC1 System enables complete downstream analysis of the
sample including whole cell imaging and proteomic analysis and full genomic
and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system and associated
consumables. The clinical services business is offered through ANGLE's
GCP-compliant laboratories.  Services include custom made assay development
and clinical trial testing for pharma.

 

Over 80 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAVVLFBXFLLFBQ